Pulse Biosciences, Inc.

NasdaqCM PLSE

Pulse Biosciences, Inc. Free Cash Flow Yield on January 14, 2025: -3.22%

Pulse Biosciences, Inc. Free Cash Flow Yield is -3.22% on January 14, 2025, a 55.55% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Pulse Biosciences, Inc. 52-week high Free Cash Flow Yield is -2.49% on December 04, 2024, which is 22.63% above the current Free Cash Flow Yield.
Pulse Biosciences, Inc. 52-week low Free Cash Flow Yield is -9.77% on April 25, 2024, which is -203.26% below the current Free Cash Flow Yield.
Pulse Biosciences, Inc. average Free Cash Flow Yield for the last 52 weeks is -5.08%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: PLSE

Pulse Biosciences, Inc.

CEO	Mr. Robert W. Duggan
IPO Date	May 18, 2016
Location	United States
Headquarters	3957 Point Eden Way
Employees	56
Sector	Health Care
Industries Biotechnology Energy Storage & Batteries Pharmaceuticals

Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Key trends

Past 5 years